Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Suzhou Zelgen Biopharmaceuticals Co.,Ltd appears in 12 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials12
Recruiting shown9
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

12 shown
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerNCT07231445 · lead sponsor · 2026-04-21
RECRUITING
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerNCT07189455 · lead sponsor · 2025-12-12
RECRUITING
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaNCT07038096 · lead sponsor · 2025-09-23
RECRUITING
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerNCT06903377 · lead sponsor · 2025-05-23
RECRUITING
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid TumorsNCT06938880 · lead sponsor · 2025-05-20
RECRUITING
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung CancerNCT06592638 · lead sponsor · 2025-03-31
RECRUITING
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerNCT06283719 · lead sponsor · 2024-09-02
RECRUITING
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.NCT06440057 · lead sponsor · 2024-08-29
RECRUITING
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaNCT05978284 · lead sponsor · 2023-10-27
RECRUITING
Study of ZG006 in Participants With Neuroendocrine Prostate CancerNCT07024277 · lead sponsor · 2025-08-01
NOT_YET_RECRUITING
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibNCT04211922 · lead sponsor · 2020-01-21
TERMINATED
Study of Alkotinib in Patients With Advanced Non Small Cell Lung CancerNCT03607188 · lead sponsor · 2018-10-18
COMPLETED

Drugs studied in this sponsor's trials

1 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Suzhou Zelgen Biopharmaceuticals Co.,Ltd as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Sponsor roles

lead sponsor12
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.